Myelodysplastic Syndrome: Competitive Landscape

Myelodysplastic Syndrome: Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Myelodysplastic Syndrome Therapeutics.

• GlobalData epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Myelodysplastic Syndrome (MDS) infection in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029.
• MDS is managed through a combination of supportive care, chemotherapy, and targeted therapies.
• The MDS pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase III development, and 87 assets in Phase II.
• Over the past decade, 1,229 clinical trials have been conducted in MDS.
• During the past decade, partnerships were most prevalent in North America and Europe.

Scope

GlobalData’s Myelodysplastic Syndrome Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Myelodysplastic Syndrome Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Myelodysplastic Syndrome Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.